Glucotrack (Nasdaq: GCTK) and its operating business Lōkahi Therapeutics announced completion of a bridge financing intended to support strategic growth, integration of the recently combined Glucotrack–Lōkahi platform, and future capital markets initiatives. E.F. Hutton & Co. acted as exclusive financial advisor and placement agent and will continue to assist in evaluating additional financing options to strengthen the balance sheet and advance corporate objectives.
Lōkahi plans to keep executing its ai²™-driven strategy, including the ai² Futures Lab program, which works with universities to identify and assess distressed or under-prioritized clinical assets for potential inclusion in its biopharmaceutical development platform.
Loading…
Loading translation…
Positive
- Bridge financing completed to support growth, platform integration, and capital markets plans
- E.F. Hutton & Co. engaged as exclusive advisor and placement agent for current and future financings
- ai² Futures Lab program continues sourcing and evaluating external clinical assets for Lōkahi’s pipeline
The July 17 release gives no bridge-financing amount or terms describing dilution, conversion, or consideration, so the completed financing’s effect on existing common holders’ ownership or the company’s funding position cannot be established from this disclosure.
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 14 | Positive | -0.0% |
Completion of strategic Glucotrack–Lōkahi business combination and control shift. |
|
| Jul 08 | Positive | +1.7% |
USPTO Notice of Allowance expanding protection of implantable CBGM platform. |
|
| May 26 | Positive | +18.9% |
Highlighting implantable CBGM technology and new data at ADA 2026 meeting. |
|
| May 14 | Neutral | -3.0% |
Quarterly results with narrower net loss and CBGM development updates. |
|
| May 07 | Positive | +0.8% |
IDE filing to FDA to start U.S. clinical study of implantable CBGM. |
Recent history shows GCTK often trading higher on positive development news, with the strategic business combination drawing a flat-to-slightly-negative price reaction.
bridge financing
financial
“announced the completion of a bridge financing designed to support the Company’s strategic growth”
Bridge financing is short-term funding a company uses to cover expenses until longer-term financing or a sale comes through. Think of it as a temporary loan or financial “bridge” that keeps operations running—similar to borrowing to cover a gap between paychecks. Investors watch bridge financing because it can signal cash pressure, potential dilution, or higher costs to raise capital, which affect a company’s risk and value.
business combination
regulatory
“follows the completion of the strategic business combination between Glucotrack and Lōkahi”
A business combination happens when two or more companies join together to operate as one, like two friends merging their teams into a single group. This is important because it can change how companies grow, compete, and make money, often making them bigger and more powerful in the market.
placement agent
financial
“served as exclusive financial advisor and placement agent in connection with the bridge financing”
A placement agent is a professional or firm that helps organizations raise money from investors, such as individuals, institutions, or funds. They act like matchmakers, connecting those seeking investments with the right investors and guiding the process to ensure successful funding. For investors, they can provide access to exclusive opportunities and help navigate complex fundraising efforts.
capital markets
financial
“future capital markets activities”
Capital markets are places where people and organizations buy and sell long-term investments like stocks and bonds. They help connect those who need money to grow or fund projects with investors looking to earn returns over time. For investors, capital markets are important because they offer opportunities to invest, save, and grow their wealth through a variety of financial assets.
AI-generated analysis. How Rhea-AI works. Not financial advice.
RUTHERFORD, N.J. and SAN DIEGO, July 17, 2026 (GLOBE NEWSWIRE) — Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), together with its operating business Lōkahi Therapeutics™ (“Lōkahi”), a clinical-stage biopharmaceutical company advancing innovative non-opioid biologic therapies and applying its proprietary ai²™ methodology to identify and develop high-value healthcare opportunities, today announced the completion of a bridge financing designed to support the Company’s strategic growth objectives, including the continued advancement of the combined Glucotrack–Lōkahi platform and other anticipated capital markets activities. The bridge financing follows the completion of the strategic business combination between Glucotrack and Lōkahi, announced on July 14, 2026.
E.F. Hutton & Co. served as exclusive financial advisor and placement agent in connection with the bridge financing and continues to support the Company as it evaluates additional financing opportunities intended to strengthen its balance sheet, advance corporate initiatives, and support long-term value creation.
“The successful completion of this bridge financing represents an important step in our broader strategic plan,” said Erik Emerson, Chief Executive Officer of Glucotrack, who previously served as Chief Executive Officer of Lōkahi Therapeutics™. “We appreciate the support and guidance of E.F. Hutton & Co. as we complete the integration of Glucotrack and Lōkahi and evaluate additional capital formation opportunities. We believe these initiatives position the Company to expand its strategic capabilities and create a stronger platform for future growth.”
The bridge financing provides the Company with additional financial flexibility as it works toward completing strategic initiatives currently under evaluation. Subject to customary conditions and applicable approvals, Lōkahi intends to continue executing its strategy of identifying, evaluating, and advancing opportunities that complement its biopharmaceutical development platform and ai²™ operating model.
As part of that strategy, Lōkahi is continuing to advance the ai² Futures Lab, the first applied product of its ai² methodology. The program leverages Lōkahi’s university relationships to identify and evaluate distressed, shelved, under-prioritized, or abandoned clinical assets that may contain unrecognized strategic value, with student teams conducting structured clinical, commercial, regulatory, intellectual property, and strategic assessments before opportunities are considered for Lōkahi intake.
“We are pleased to support Lōkahi Therapeutics during this important stage of its development,” said Joseph T. Rallo, Chief Executive Officer of E.F. Hutton & Co. “Lōkahi has established a differentiated strategy that combines clinical-stage biotechnology development with a disciplined approach to identifying and unlocking value from strategic opportunities, now anchored within Glucotrack’s publicly listed platform. We look forward to supporting management as it executes its objectives and evaluates future financing initiatives.” Glucotrack expects to provide additional information regarding the combined company’s strategic initiatives and potential financing activities as appropriate and in accordance with applicable securities laws.
About Lōkahi Therapeutics™
Lōkahi Therapeutics™ is redefining intelligent medicine—where clinical judgment, scientific rigor, and human insight guide every decision. Lōkahi is advancing non-opioid biologic therapeutic candidates and applies its proprietary ai²™ (“Actual Intelligence”) methodology to evaluate, acquire, develop, and advance differentiated healthcare opportunities. At the core of Lōkahi’s strategy is the disciplined integration of human expertise, scientific evaluation, and technology-enabled decision making. For more information, visit www.lokahithera.com.
About Glucotrack, Inc.
Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes, including a long-term implantable continuous blood glucose monitoring system. The Glucotrack CBGM is an Investigational Device and is limited by federal (or United States) law to investigational use. For more information, please visit www.glucotrack.com.
About E.F. Hutton & Co.
E.F. Hutton & Co. is a full-service investment bank and broker-dealer headquartered in New York City, serving corporations, financial sponsors, and institutional investors across the U.S., Asia, Europe, the UAE, and Latin America. We provide a comprehensive range of investment banking and capital markets services across our specialized divisions, delivering integrated solutions at every stage of the capital lifecycle. For more information, please visit www.efhutton.com.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “anticipate”, “believe”, “expect”, “plan,” and “will” are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate only to events as of the date on which the statements are made, and Glucotrack undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. All of the forward-looking statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated by Glucotrack will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations. Readers are cautioned that certain important factors may affect Glucotrack’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Glucotrack’s results include, but are not limited to, the ability of Glucotrack to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to merger integration; risks relating to the receipt (and timing) of regulatory approvals (including U.S. Food and Drug Administration approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks relating to Glucotrack’s future distribution agreements; risks relating to its ability to hire and retain qualified personnel, including sales and distribution personnel; and the additional risk factors described in Glucotrack’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2025 as filed with the SEC on March 30, 2026.
Contact:
Glucotrack
Lōkahi Therapeutics™
FAQ
What did Glucotrack (GCTK) announce about new financing with Lōkahi Therapeutics on July 17, 2026?
Glucotrack announced completion of a bridge financing to support its strategic growth plans. According to Glucotrack, the funds are intended to advance the combined Glucotrack–Lōkahi platform and help prepare for additional capital markets and corporate initiatives.
How is E.F. Hutton & Co. involved with Glucotrack (GCTK) and Lōkahi Therapeutics financing?
E.F. Hutton & Co. served as exclusive financial advisor and placement agent for the bridge financing. According to Glucotrack, E.F. Hutton will continue supporting the company as it evaluates additional financing opportunities to strengthen the balance sheet and advance strategic objectives.
How does the bridge financing relate to the Glucotrack and Lōkahi Therapeutics business combination?
The bridge financing follows the recently completed strategic business combination between Glucotrack and Lōkahi. According to Glucotrack, the financing is designed to aid integration of the combined platform and support ongoing corporate initiatives and potential future capital markets activities.
What strategic initiatives will Glucotrack (GCTK) and Lōkahi Therapeutics pursue after this bridge financing?
Glucotrack plans to continue evaluating strategic initiatives and potential financing activities. According to Glucotrack, Lōkahi will keep advancing its biopharmaceutical development platform, ai²™ operating model, and ai² Futures Lab to identify and progress complementary clinical-stage opportunities.
What is Lōkahi Therapeutics’ ai² Futures Lab mentioned in the Glucotrack (GCTK) update?
The ai² Futures Lab is an applied program within Lōkahi’s ai² methodology. According to Lōkahi, it partners with universities to identify distressed, shelved, or under-prioritized clinical assets and uses structured assessments to decide which opportunities may enter Lōkahi’s development platform.
Will Glucotrack (GCTK) provide more details on future financing or strategy after this bridge financing?
Glucotrack plans to share additional information on strategic initiatives and potential financings when appropriate. According to Glucotrack, any future disclosures will be made in line with applicable securities laws and as the company’s evaluations progress.
